Pulmonary Hypertension

• A descriptive analysis of pulmonary arterial hypertension in children from the East of Scotland 1983 to 2008
• Adverse effect of Estrogen on Bone Morphogenetic Protein Receptor signal pathway in pulmonary arterial endothelial cells
• Beneficial Effect of Oral Bosentan in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
• Bosentan Promotes Incorporation of Bone Marrow-Derived Endothelial Progenitor Cells but Inhibits Infiltration of Macrophages into Pulmonary Vascular Lesions in Mice: A New Mechanism of Bosentan in Inhibiting Pulmonary Hypertension
• Cardiac function in pulmonary hypertension: the usefulness of biochemical markers and echo in management of CDH infants
• Characteristics and Outcomes of Children with Pulmonary Arterial Hypertension Referred to a Single Statewide Service
• Combination therapy of bosentan, beraprost and HOT improve pulmonary artery hypertension related to congenital heart disease in contraindications for right heart bypass surgery
• Decline in Arterial pO2 after Exercise can Help Stratify Patients with Large Atrial Septal Defect and Pulmonary Hypertension
• Differential diagnosis of children with hypertension
• Does Anticoagulation in Eisenmenger Syndrome Alter Long-Term Survival?
• Effect of hydrogen sulfide on the apoptosis of pulmonary artery smooth muscle cell in rats with pulmonary hypertension induced by high pulmonary blood flow
• Efficacy of Bosentan Treatment in Children with Eisenmenger Syndrome and Primary Pulmonary Hypertension
• Efficacy of combination of Pulmonary Artery Banding and oral Sildenafil in children with early Eisenmenger VSD : 3 year Follow up
• Estimation of Pulmonary Vascular Resistance: Correlation between Echocardiography and Catheterization Data In Patients With Congenital Heart Disease
• Fetal and neonatal ventricular load markers in experimental congenital diaphragmatic hernia
• Gene Expression of Endothelin-1 and Endothelin Receptor A on Monocrotaline-Induced Pulmonary Hypertension in Rats after Bosentan Treatment
• Gene Expression of Nitric Oxide Synthase and Matrix Metalloproteinase-2 in Monocrotaline-Induced Pulmonary Hypertension in Rats
• High altitude pulmonary edema (HAPE)
• Hypoventilation easily leads to severe pulmonary hypertension in Down syndrome patients with congenital heart disease
• Impact on clinical parameters using new farmacological therapies in patients with pulmonary arterial hypertension due to congenital heart disease
• Inhaled iloprost In Control Of Postoperative Inhaled iloprost In Control Of Postoperative Pulmonary Hypertension After Pediatric Cardiac Surgery:A One Year, Single Center, Open Label Pilot Trial
• Intravenous Transplantation of Syngenic Bone Marrow-derived Mononuclear Cells Improves Pulmonary Artery hypertension by Paracrine Effect through VEGF-VEGF Receptor System
• Oral Sildenafil for Persistent Pulmonary Hypertension Early After Congenital Cardiac Surgery
• Outcome of children with pulmonary arterial hypertension in the era of antiproliferative medication
• Outcome of surgical repair of patients with left-to-right (LR) shunt lesion and severe pulmonary arterial hypertension (PAH)
• Paediatric Pulmonary Arterial Hypertension: Effects of Long-Term Treatment with Bosentan
• Pretreatment with phosphodiesterase inhibitors(Sildenafil/Milrinone) prevents pulmonary hypertensive crisis in children undergoing cardiac surgery
• Prevalence and prognostic value of acute pulmonary vasodilator response in children and adults with pulmonary arterial hypertension
• Protecting the lung and the heart in experimental acute lung injury: Low tidal voulme ventilation in combination with intravenous ET-1 receptor blockade by tezosentan
• Pulmonary and systemic hypertension in the setting of Moya-Moya disease due to disseminated fibromuscular dysplasia
• Pulmonary Veno-Occlusive Disease in a Child with Prothrombine Gene Mutation
• Relationship of VEGF/receptors level with hemodynamic parameters in cyanotic congenital heart disease with diminished pulmonary flow
• Reversible Course of Pulmonary Arterial Hypertension
• Right ventricular pressure during exercise in adolescents with atrial or ventricular septal defect
• Role of caveolin-1 in pulmonary hypertension
• Role of heme oxygenase-1 and endothelial progenitor cells in the beneficial effects of erythropoietin on flow-associated pulmonary arterial hypertension
• Selection of muscular ventricular septal occluders versus duct occluders to close large patent arterial ducts with severe pulmonary arterial hypertension
• Severe Pulmonary Hypertension in an Infant Girl with Incontinentia Pigmenti
• Single-Center Experience in Large Cohort of Patients with Pulmonary Arterial Hypertension Related to Congenital Heart Disease over 15 years: Effect of New Therapies
• The changes of pulmonary arterial pressure after tonsillectomy and sdonoidectomy in childhood
• The effect of living in the high plateau on cardiovascular system
• The Effect of Perioperative inhaled Iloprost Treatment on Congenital Heart Disease with Pulmonary Arterial Hypertension
• The Impact of Current Therapies on Survival in Children with Idiopathic Pulmonary Arterial Hypertension
• The role of Rho A/Rho-kinase pathway on the pathogenesis of pulmonary hypertension secondary to left ventricular dysfunction
• Twenty three years old man who was treated as PPH for 11 years finally revealed as multiple peripheral PS: A case report
• Use of bosentan hydrate, an endothelin-1 dual receptor blocker, for treatment of impaired pulmonary circulation after congenital cardiac surgery
• Use of ductus arteriosus in management of pulmonary artery hypertension
• Use of Iloprost in Infant of Bronchopulmonary Dysplasia with Pulmonary Arterial Hypertension
• Vasoreactivity test in pulmonary arterial hypertension due to congenital heart disease (Eisenmenger syndrome): significance and impact on long term prognosis
• Ventricular septal defect closure with double patch technique in paediatric patients with increased pulmonary vascular resistance

50 abstracts